Clinical and economic outcomes of patients with cardiorenal and metabolic diseases: a real-world analysis in a single Italian Local Health Unit
Expert Review of Pharmacoeconomics & Outcomes Research · 2025
DOI: 10.1080/14737167.2025.2504944 ↗Kurz gefasst
Fachartikel in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2025. Verfasst von Valentina Perrone und 11 weiteren Autor:innen. Beteiligte Einrichtung: CliCon S.r.l. Società Benefit Health, Economics & Outcomes Research, Bologna, Italy. Hauptthemen laut MEDLINE: Metabolic Diseases. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AstraZeneca.
Abstract (Originalsprache)
BACKGROUND: This single-center real-world analysis describes the epidemiology, demographic and clinical characteristics, mortality, and therapeutic-care management of patients grouped by the presence of seven cardiorenal and metabolic diseases. RESEARCH DESIGN AND METHODS: From the administrative databases of a single Local Health Unit in Southern Italy with approximately 400,000 inhabitants, the following cohorts were identified during 2020-2021: (1) type 1 diabetes (T1D); (2) type 2 diabetes (T2D); (3) heart failure (HF); (4) chronic kidney disease (CKD); (5) hyperkalemia (HK); (6) nonalcoholic steatohepatitis (NASH); (7) dyslipidemia. The variables examined for each cohort were: prevalence, demographic and clinical data, comorbidity profile, biochemical tests, hospitalization rates, therapies, 1-year all-cause mortality. RESULTS: From a cohorts overview, the population with cardiorenal and metabolic diseases was characterized by a high proportion of elderly subjects, a relatively high rate of all-cause hospitalizations and elevated mortality. The analysis of the comorbidity pattern in each group confirmed the interrelation of these pathologies, with diabetes, dyslipidemia, and CKD as the most common concomitant conditions. CONCLUSIONS: From these real-world data, patients with cardiorenal and metabolic diseases emerge as a fragile population, with multimorbidity, and a substantial risk of hospitalizations and death, confirming as chronicity represent a priority issue for health systems.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- CliCon S.r.l. Società Benefit Health, Economics & Outcomes Research, Bologna, Italy.
- Dipartimento Farmaceutico ASL BAT (Barletta-Trani-Andria), Trani, Italy.
- Medical Evidence, AstraZeneca S.p.A, Milan, Italy.
- Medical Affairs, AstraZeneca S.p.A, Milan, Italy.
- Market Access, AstraZeneca S.p.A, Milan, Italy.
Förderung
- AstraZeneca
Zitieren
APA
Perrone, V., Ancona, D. D., Gnesi, M., Mongelli, V., Migliaccio, S., Renato Colanero, F., Antonio Lenoci, E., Bonfanti, L., Leogrande, M., Cappuccilli, M., Procacci, C., & Degli Esposti, L. (2025). Clinical and economic outcomes of patients with cardiorenal and metabolic diseases: a real-world analysis in a single Italian Local Health Unit. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2025.2504944
Vancouver
Perrone V, Ancona DD, Gnesi M, Mongelli V, Migliaccio S, Renato Colanero F, et al. Clinical and economic outcomes of patients with cardiorenal and metabolic diseases: a real-world analysis in a single Italian Local Health Unit. Expert Review of Pharmacoeconomics & Outcomes Research. 2025. doi:10.1080/14737167.2025.2504944
BibTeX
@article{Perrone2025,
author = {Perrone, Valentina and Ancona, Domenica Daniela and Gnesi, Marco and Mongelli, Valentina and Migliaccio, Sara and Renato Colanero, Felice and Antonio Lenoci, Emanuele and Bonfanti, Lidia and Leogrande, Melania and Cappuccilli, Maria and Procacci, Cataldo and Degli Esposti, Luca},
title = {Clinical and economic outcomes of patients with cardiorenal and metabolic diseases: a real-world analysis in a single Italian Local Health Unit},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2025},
doi = {10.1080/14737167.2025.2504944}
}
EUVIMED